BofA lowered the firm’s price target on Bluebird Bio to $4 from $5 and keeps a Buy rating on the shares. Shares underperformed yesterday, which was likely due to softer than expected Q4 revenue, which management attributed to cell infusion deferrals that should be recognized in Q1. Bluebird is maintaining its guidance provided in December 2023 for 85-105 patient starts across all three of its gene therapies, noted the analyst, who reiterates a Buy on upside from current trading levels on the Lyfgenia launch in the “attractive SCD market.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLUE:
- Options Volatility and Implied Earnings Moves Today, March 26, 2024
- Bluebird Bio reports Q4 revenue $7.8M, consensus $16.68M .
- Bluebird Bio price target lowered to $1.68 from $3 at Wedbush
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Bluebird Bio signs Medicaid outcomes-based agreement for Lyfgenia